PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells
Open Access
- 21 January 2016
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (11) , 12447-12463
Abstract
PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cellsKeywords
This publication has 39 references indexed in Scilit:
- LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potentialCancer Biology & Therapy, 2015
- Medulloblastoma: Toward Biologically Based ManagementSeminars in Pediatric Neurology, 2014
- Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working GroupActa Neuropathologica, 2013
- Protein phosphatase 2A: a target for anticancer therapyThe Lancet Oncology, 2013
- Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961Neuro-Oncology, 2012
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009Neuro-Oncology, 2012
- Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomasActa Neuropathologica, 2012
- High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastomaNeuro-Oncology, 2010
- From childhood to adulthood: long-term outcome of medulloblastoma patients. The Institut Curie experience (1980–2000)Journal of Neuro-Oncology, 2009
- Pediatric medulloblastoma: Toxicity of current treatment and potential role of protontherapyCancer Treatment Reviews, 2009